TRVI News and Press, Trevi Therapeutics Inc. From 02/01/22

Trevi Therapeutics (TRVI +9.8%) completed enrollment in its phase 2b/3 PRISM trial of Haduvio (nalbuphine ER) for pruritus associated with prurigo nodularis (PN). PN is a chronic inflammatory skin disease where an extremely itchy rash appears on parts of the body. The company expects to ...

Trevi Therapeutics Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus in PN Top-Line Data Expected 2Q 2022 PR Newswire NEW HAVEN, Conn. , Feb. 1, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmace...

Trevi Therapeutics Announces Clinical Trial Updates for Lead Indications Phase 2 CANAL (Chronic Cough in IPF) Planned Interim Statistical Update 1Q 2022, with Top-Line Data 1H 2022 Phase 2b/3 PRISM (Chronic Pruritus in PN) Enrollment to End January 31, 2022, with Top-Line Da...

Trevi Therapeutics to Attend Multiple Conferences in January 2022 11th Annual LifeSci Partners Corporate Access Event, January 5-7 Dermatology Summit, January 7 H.C. Wainwright BIOCONNECT Virtual Conference, January 10-13 Biotech Showcase 2022, January 10-12 and Janu...

Trevi Therapeutics to Present at 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases PR Newswire NEW HAVEN, Conn. , Nov. 15, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company foc...

Trevi Therapeutics, Inc. (TRVI) Q3 2021 Earnings Conference Call November 10, 2021, 04:30 PM ET Company Participants Jennifer Good - President and CEO Bill Forbes - Chief Development Officer Lisa Delfini - CFO Conference Call Participants Nick Rubino - Stifel Rohit Bhasin - Needham & Comp...

Trevi Therapeutics (NASDAQ:TRVI): Q3 GAAP EPS of -$0.34 beats by $0.12. As of September 30, 2021, the Company had total cash and cash equivalents of $29.3 million. Press Release For further details see: Trevi Therapeutics EPS beats by $0.12

Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 90% Enrolled, Top-Line Data Readout Expected First Half of 2022 Phase 2 CANAL (Chronic Cough in IPF) Actively Enrolling, Top-Li...

Trevi Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference PR Newswire NEW HAVEN, Conn. , Nov. 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercia...

Trevi Therapeutics to Report Q3 2021 Financial Results and Provide a Corporate Update on Wednesday, November 10, 2021 Conference Call and Webcast to be Held at 4:30 p.m. ET PR Newswire NEW HAVEN, Conn. , Nov. 3, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc....